Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/II.

Wilcox MH, Rahav G, Dubberke ER, Gabryelski L, Davies K, Berry C, Eves K, Ellison MC, Guris D, Dorr MB.

Open Forum Infect Dis. 2019 Aug 1;6(8). pii: ofz293. doi: 10.1093/ofid/ofz293.

2.

Efficacy of bezlotoxumab based on timing of administration relative to start of antibacterial therapy for Clostridium difficile infection.

Birch T, Golan Y, Rizzardini G, Jensen E, Gabryelski L, Guris D, Dorr MB.

J Antimicrob Chemother. 2018 Sep 1;73(9):2524-2528. doi: 10.1093/jac/dky182.

PMID:
29788418
3.

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.

Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim YS, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, Kartsonis N, Dorr MB; MODIFY I and MODIFY II Investigators.

N Engl J Med. 2017 Jan 26;376(4):305-317. doi: 10.1056/NEJMoa1602615.

4.

Synthesis of 5-(1-H or 1-alkyl-5-oxopyrrolidin-3-yl)-8-hydroxy-[1,6]-naphthyridine-7-carboxamide inhibitors of HIV-1 integrase.

Melamed JY, Egbertson MS, Varga S, Vacca JP, Moyer G, Gabryelski L, Felock PJ, Stillmock KA, Witmer MV, Schleif W, Hazuda DJ, Leonard Y, Jin L, Ellis JD, Young SD.

Bioorg Med Chem Lett. 2008 Oct 1;18(19):5307-10. doi: 10.1016/j.bmcl.2008.08.038. Epub 2008 Aug 14.

PMID:
18774711
5.

10-Hydroxy-7,8-dihydropyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-1,9(2H,6H)-diones: potent, orally bioavailable HIV-1 integrase strand-transfer inhibitors with activity against integrase mutants.

Wiscount CM, Williams PD, Tran LO, Embrey MW, Fisher TE, Sherman V, Homnick CF, Donnette Staas D, Lyle TA, Wai JS, Vacca JP, Wang Z, Felock PJ, Stillmock KA, Witmer MV, Miller MD, Hazuda DJ, Day AM, Gabryelski LJ, Ecto LT, Schleif WA, DiStefano DJ, Kochansky CJ, Anari MR.

Bioorg Med Chem Lett. 2008 Aug 15;18(16):4581-3. doi: 10.1016/j.bmcl.2008.07.037. Epub 2008 Jul 15.

PMID:
18657970
6.

Novel indole-3-sulfonamides as potent HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs).

Zhao Z, Wolkenberg SE, Sanderson PE, Lu M, Munshi V, Moyer G, Feng M, Carella AV, Ecto LT, Gabryelski LJ, Lai MT, Prasad SG, Yan Y, McGaughey GB, Miller MD, Lindsley CW, Hartman GD, Vacca JP, Williams TM.

Bioorg Med Chem Lett. 2008 Jan 15;18(2):554-9. Epub 2007 Nov 28. Erratum in: Bioorg Med Chem Lett. 2010 Sep 1;20(17):5360. Sanderson, Philip E J [added].

PMID:
18083561
7.

Design and synthesis of substituted 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxamides, novel HIV-1 integrase inhibitors.

Langford HM, Williams PD, Homnick CF, Vacca JP, Felock PJ, Stillmock KA, Witmer MV, Hazuda DJ, Gabryelski LJ, Schleif WA.

Bioorg Med Chem Lett. 2008 Jan 15;18(2):721-5. Epub 2007 Nov 19.

PMID:
18078751
8.

8-Hydroxy-3,4-dihydropyrrolo[1,2-a]pyrazine-1(2H)-one HIV-1 integrase inhibitors.

Fisher TE, Kim B, Staas DD, Lyle TA, Young SD, Vacca JP, Zrada MM, Hazuda DJ, Felock PJ, Schleif WA, Gabryelski LJ, Anari MR, Kochansky CJ, Wai JS.

Bioorg Med Chem Lett. 2007 Dec 1;17(23):6511-5. Epub 2007 Sep 29.

PMID:
17931865
9.

Dihydroxypyridopyrazine-1,6-dione HIV-1 integrase inhibitors.

Wai JS, Kim B, Fisher TE, Zhuang L, Embrey MW, Williams PD, Staas DD, Culberson C, Lyle TA, Vacca JP, Hazuda DJ, Felock PJ, Schleif WA, Gabryelski LJ, Jin L, Chen IW, Ellis JD, Mallai R, Young SD.

Bioorg Med Chem Lett. 2007 Oct 15;17(20):5595-9. Epub 2007 Aug 22.

PMID:
17822898
10.

Synthesis of novel HIV protease inhibitors (PI) with activity against PI-resistant virus.

Raghavan S, Lu Z, Beeson T, Chapman KT, Schleif WA, Olsen DB, Stahlhut M, Rutkowski CA, Gabryelski L, Emini E, Tata JR.

Bioorg Med Chem Lett. 2007 Oct 1;17(19):5432-6. Epub 2007 Jul 31.

PMID:
17692518
11.

A potent and orally active HIV-1 integrase inhibitor.

Egbertson MS, Moritz HM, Melamed JY, Han W, Perlow DS, Kuo MS, Embrey M, Vacca JP, Zrada MM, Cortes AR, Wallace A, Leonard Y, Hazuda DJ, Miller MD, Felock PJ, Stillmock KA, Witmer MV, Schleif W, Gabryelski LJ, Moyer G, Ellis JD, Jin L, Xu W, Braun MP, Kassahun K, Tsou NN, Young SD.

Bioorg Med Chem Lett. 2007 Mar 1;17(5):1392-8. Epub 2006 Dec 3.

PMID:
17194584
12.

A series of 5-aminosubstituted 4-fluorobenzyl-8-hydroxy-[1,6]naphthyridine-7-carboxamide HIV-1 integrase inhibitors.

Guare JP, Wai JS, Gomez RP, Anthony NJ, Jolly SM, Cortes AR, Vacca JP, Felock PJ, Stillmock KA, Schleif WA, Moyer G, Gabryelski LJ, Jin L, Chen IW, Hazuda DJ, Young SD.

Bioorg Med Chem Lett. 2006 Jun 1;16(11):2900-4. Epub 2006 Mar 22.

PMID:
16554152
13.

Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus.

Lu Z, Bohn J, Rano T, Rutkowski CA, Simcoe AL, Olsen DB, Schleif WA, Carella A, Gabryelski L, Jin L, Lin JH, Emini E, Chapman K, Tata JR.

Bioorg Med Chem Lett. 2005 Dec 1;15(23):5311-4. Epub 2005 Oct 3.

PMID:
16203148
14.

Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.

Liang X, Casimiro DR, Schleif WA, Wang F, Davies ME, Zhang ZQ, Fu TM, Finnefrock AC, Handt L, Citron MP, Heidecker G, Tang A, Chen M, Wilson KA, Gabryelski L, McElhaugh M, Carella A, Moyer C, Huang L, Vitelli S, Patel D, Lin J, Emini EA, Shiver JW.

J Virol. 2005 Oct;79(19):12321-31.

15.

A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells.

Embrey MW, Wai JS, Funk TW, Homnick CF, Perlow DS, Young SD, Vacca JP, Hazuda DJ, Felock PJ, Stillmock KA, Witmer MV, Moyer G, Schleif WA, Gabryelski LJ, Jin L, Chen IW, Ellis JD, Wong BK, Lin JH, Leonard YM, Tsou NN, Zhuang L.

Bioorg Med Chem Lett. 2005 Oct 15;15(20):4550-4.

PMID:
16102965
16.

Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques.

Hazuda DJ, Young SD, Guare JP, Anthony NJ, Gomez RP, Wai JS, Vacca JP, Handt L, Motzel SL, Klein HJ, Dornadula G, Danovich RM, Witmer MV, Wilson KA, Tussey L, Schleif WA, Gabryelski LS, Jin L, Miller MD, Casimiro DR, Emini EA, Shiver JW.

Science. 2004 Jul 23;305(5683):528-32. Epub 2004 Jul 8.

17.

Design and synthesis of highly potent HIV protease inhibitors with activity against resistant virus.

Lu Z, Raghavan S, Bohn J, Charest M, Stahlhut MW, Rutkowski CA, Simcoe AL, Olsen DB, Schleif WA, Carella A, Gabryelski L, Jin L, Lin JH, Emini E, Chapman K, Tata JR.

Bioorg Med Chem Lett. 2003 May 19;13(10):1821-4.

PMID:
12729673
18.

Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells.

Zhuang L, Wai JS, Embrey MW, Fisher TE, Egbertson MS, Payne LS, Guare JP Jr, Vacca JP, Hazuda DJ, Felock PJ, Wolfe AL, Stillmock KA, Witmer MV, Moyer G, Schleif WA, Gabryelski LJ, Leonard YM, Lynch JJ Jr, Michelson SR, Young SD.

J Med Chem. 2003 Feb 13;46(4):453-6.

PMID:
12570367
19.

Combinatorial library of indinavir analogues: replacement for the aminoindanol at P2'.

Raghavan S, Yang Z, Mosley RT, Schleif WA, Gabryelski L, Olsen DB, Stahlhut M, Kuo LC, Emini EA, Chapman KT, Tata JR.

Bioorg Med Chem Lett. 2002 Oct 21;12(20):2855-8.

PMID:
12270162
20.

Indinavir analogues with blocked metabolism sites as HIV protease inhibitors with improved pharmacological profiles and high potency against PI-resistant viral strains.

Cheng Y, Zhang F, Rano TA, Lu Z, Schleif WA, Gabryelski L, Olsen DB, Stahlhut M, Rutkowski CA, Lin JH, Jin L, Emini EA, Chapman KT, Tata JR.

Bioorg Med Chem Lett. 2002 Sep 2;12(17):2419-22.

PMID:
12161147
21.

A combinatorial library of indinavir analogues and its in vitro and in vivo studies.

Cheng Y, Rano TA, Huening TT, Zhang F, Lu Z, Schleif WA, Gabryelski L, Olsen DB, Stahlhut M, Kuo LC, Lin JH, Xu X, Jin L, Olah TV, McLoughlin DA, King RC, Chapman KT, Tata JR.

Bioorg Med Chem Lett. 2002 Feb 25;12(4):529-32.

PMID:
11844665
22.

4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells.

Wai JS, Egbertson MS, Payne LS, Fisher TE, Embrey MW, Tran LO, Melamed JY, Langford HM, Guare JP Jr, Zhuang L, Grey VE, Vacca JP, Holloway MK, Naylor-Olsen AM, Hazuda DJ, Felock PJ, Wolfe AL, Stillmock KA, Schleif WA, Gabryelski LJ, Young SD.

J Med Chem. 2000 Dec 28;43(26):4923-6. No abstract available.

PMID:
11150161
23.

Combinatorial diversification of indinavir: in vivo mixture dosing of an HIV protease inhibitor library.

Rano TA, Cheng Y, Huening TT, Zhang F, Schleif WA, Gabryelski L, Olsen DB, Kuo LC, Lin JH, Xu X, Olah TV, McLoughlin DA, King R, Chapman KT, Tata JR.

Bioorg Med Chem Lett. 2000 Jul 17;10(14):1527-30.

PMID:
10915042
24.

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.

Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, Espeseth A, Gabryelski L, Schleif W, Blau C, Miller MD.

Science. 2000 Jan 28;287(5453):646-50.

25.

Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor.

Condra JH, Holder DJ, Schleif WA, Blahy OM, Danovich RM, Gabryelski LJ, Graham DJ, Laird D, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Yang T, Chodakewitz JA, Deutsch PJ, Leavitt RY, Massari FE, Mellors JW, Squires KE, Steigbigel RT, Teppler H, Emini EA.

J Virol. 1996 Dec;70(12):8270-6.

26.

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.

Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, et al.

Nature. 1995 Apr 6;374(6522):569-71.

PMID:
7700387

Supplemental Content

Loading ...
Support Center